| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary targets of Strictosamide include inflammatory pathways, Plasmodium parasites, and fungal pathogens. As an anti-inflammatory agent, it plays important roles in inflammation and inflammatory pain. As an antiplasmodial agent, it inhibits Plasmodium parasites. As an antifungal agent, it inhibits fungal pathogens. The compound does not have a defined receptor target but exerts its effects through multiple mechanisms.
|
|---|---|
| ln Vitro |
In vitro, Strictosamide demonstrates anti-inflammatory, antiplasmodial, and antifungal activities. As a monoterpene indole alkaloid, it has been characterized for its diverse biological activities. The anti-inflammatory activity involves modulation of inflammatory pathways. The antiplasmodial and antifungal activities are concentration-dependent and have been demonstrated in standard bioassays.
|
| ln Vivo |
In vivo, Strictosamide has important effects on inflammation and inflammatory pain. The compound has been shown to have anti-inflammatory and analgesic activities in animal models. However, detailed in vivo pharmacokinetic and pharmacodynamic studies are limited. The compound's in vivo efficacy is associated with its anti-inflammatory, antiplasmodial, and antifungal activities.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Strictosamide typically involve anti-inflammatory mechanism studies and antimicrobial susceptibility testing. For anti-inflammatory studies, LPS-stimulated macrophages are treated with Strictosamide, and inflammatory cytokine production is measured. For antiplasmodial and antifungal testing, parasites and fungi are treated with serial dilutions of Strictosamide, and IC₅₀ values are determined.
|
| Cell Assay |
In vitro cellular assays for Strictosamide involve testing its anti-inflammatory, antiplasmodial, and antifungal activities. For anti-inflammatory studies, macrophages are stimulated with LPS and treated with Strictosamide (1-50 µM), and cytokine levels are measured by ELISA. For antiplasmodial studies, Plasmodium-infected red blood cells are treated with the compound. For antifungal studies, fungal cultures are treated with the compound, and growth inhibition is measured.
|
| Animal Protocol |
In vivo animal studies for Strictosamide involve testing its anti-inflammatory and analgesic activities. Animal models of inflammation (e.g., carrageenan-induced paw edema, formalin test) are used. Animals are treated with Strictosamide via oral or intraperitoneal administration, and inflammatory markers and pain responses are assessed. The compound demonstrates anti-inflammatory and analgesic activities in vivo.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Strictosamide include a molecular weight of 498.53 and a molecular formula of C₂₆H₃₀N₂O₈. The compound is intended for research use only and has not been approved for clinical use. Detailed pharmacokinetic parameters such as half-life, oral bioavailability, and tissue distribution are not well characterized in the available literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Strictosamide includes slight toxicity. As a natural product, it is generally considered to have moderate toxicity. Standard toxicity studies would include assessment of acute oral toxicity, repeated-dose toxicity, and genotoxicity in animal models. The compound is intended for research use only and is not approved for clinical use.
|
| References | |
| Additional Infomation |
Strictosamide are members of the β-carboline class of compounds. They have been reported in Hedyotis diffusa, Uncaria rhynchophylla, and other organisms for which relevant data are available.
Strictosamide (CAS 23141-25-5) has a molecular formula of C₂₆H₃₀N₂O₈ and a molecular weight of 498.53. It is a monoterpene indole alkaloid that plays important roles in inflammation and inflammatory pain. The compound possesses antiplasmodial and antifungal activities and is used in research for its anti-inflammatory, antiplasmodial, and antifungal properties. It is intended for research use only and is not approved for clinical use. |
| Molecular Formula |
C26H30N2O8
|
|---|---|
| Molecular Weight |
498.53
|
| Exact Mass |
498.2
|
| CAS # |
23141-25-5
|
| PubChem CID |
10345799
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
816.2±65.0 °C at 760 mmHg
|
| Flash Point |
447.4±34.3 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.716
|
| LogP |
-0.55
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
36
|
| Complexity |
899
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C=C[C@@H]1[C@@H]2C[C@H]3C4=C(CCN3C(=O)C2=CO[C@H]1O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C6=CC=CC=C6N4
|
| InChi Key |
LBRPLJCNRZUXLS-IUNANRIWSA-N
|
| InChi Code |
InChI=1S/C26H30N2O8/c1-2-12-15-9-18-20-14(13-5-3-4-6-17(13)27-20)7-8-28(18)24(33)16(15)11-34-25(12)36-26-23(32)22(31)21(30)19(10-29)35-26/h2-6,11-12,15,18-19,21-23,25-27,29-32H,1,7-10H2/t12-,15+,18+,19-,21-,22+,23-,25+,26+/m1/s1
|
| Chemical Name |
(1S,18S,19R,20S)-19-ethenyl-18-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,15-pentaen-14-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (200.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0059 mL | 10.0295 mL | 20.0590 mL | |
| 5 mM | 0.4012 mL | 2.0059 mL | 4.0118 mL | |
| 10 mM | 0.2006 mL | 1.0029 mL | 2.0059 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
